A carregar...
Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
PURPOSE: The National Cancer Institute has completed a first-in-human clinical pharmacodynamic (PD) trial of the targeted agent ABT-888, a poly (ADP-ribose) polymerase (PARP) inhibitor, under the auspices of the US Food and Drug Administration's Exploratory Investigational New Drug Application....
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2766769/ https://ncbi.nlm.nih.gov/pubmed/18980982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0214 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|